BLLN · BillionToOne, Inc.
$126.08
+4.42% last session
End-of-day data · updated 2026-07-28
Market cap
$6B
Enterprise value
$5B
Trailing P/E
237.0
Forward P/E
124.3
Dividend yield
—
Beta
—
Avg volume
1M
Employees
1K
2D change
—
5D change
-0.74%
10D change
-1.79%
30D change
8.30%
60D change
29.29%
MTD change
4.62%
YTD change
56.38%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BLLN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-29
Latest call per bank · past 12 months
JP Morgan
Overweight$125
-0.9% vs priceWells Fargo
Equal-Weight$90.00
-28.6% vs priceJefferies
Hold$117
-7.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-29 | Guggenheim | Initiates | Buy | $120 → $125 |
| 2026-05-13 | Guggenheim | Maintains | Buy | $100 → $120 |
| 2026-05-07 | JP Morgan | Maintains | Overweight | $120 → $125 |
| 2026-05-07 | BTIG | Maintains | Buy | $140 → $130 |
| 2026-03-30 | Guggenheim | Maintains | Buy | $120 → $100 |
| 2026-03-05 | Wells Fargo | Maintains | Equal-Weight | $110 → $90.00 |
| 2026-03-05 | Guggenheim | Reiterates | Buy | $120 |
| 2026-03-05 | BTIG | Maintains | Buy | $160 → $140 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 64 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 23.4% above the 50-day MA ($108.30).
- MACD (12,26,9): MACD histogram is negative (-0.47) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($133.64).
BLLN Price Chart
Loading chart for BLLN…
Fundamentals
About BillionToOne, Inc.
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a methylation-based assay that quantifies the amount of cancer at the single molecule level without requiring a tissue biopsy, enabling real-time monitoring of patient response to therapy with unprecedented precision. BillionToOne, Inc. was incorporated in 2016 and is headquartered in Menlo Park, California.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$208B -3.3% YTD
DHR
Danaher Corporation
$138B -13.8% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -17.8% YTD
A
Agilent Technologies, Inc.
$39B 1.9% YTD
NTRA
Natera, Inc.
$37B 12.6% YTD
IQV
IQVIA Holdings, Inc.
$36B -5.4% YTD
WAT
Waters Corporation
$36B -2.3% YTD
ILMN
Illumina, Inc.
$29B 44.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.